Relapse incidence is predicted by expansion of CD8⁺ T-cell clones 14 days post-DLI. (A) Cumulative incidence curves are shown with relapse incidence (CIR, solid lines) and nonrelapse mortality (NRM, dotted lines) as competing events for patients without clonal expansion (red; n = 6) and for patients with clonal expansion (blue; n = 13) of CD8⁺TRB repertoire at first sampling time point post-DLI (on average d+14). Expansion was assessed via inverse Simpson’s index (1/D) and compared with the pre-DLI time point. CIR and NRM were analyzed by means of cumulative incidence curves using Gray’s test (CIR, P = .0040; NRM, P = .1502). (B) Analysis of relapse-free survival (RFS) between patients without clonal expansion (red; n = 6) and for patients with clonal expansion (blue; n = 13) of CD8⁺TRB repertoire at first sampling time point post-DLI (on average d+14). Statistical analysis was done with univariate Cox regression model (P = .0150). (C) Analysis of overall survival (OS) between patients without clonal expansion (red; n = 6) and for patients with clonal expansion (blue; n = 13) of CD8⁺TRB repertoire at first sampling time point post-DLI (on average d+14). Statistical analysis was done with univariate Cox regression model (P = .9280).